Clinical Trials › NCT03362294
Active, Not RecruitingPhase 2
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Sponsored by Mapi Pharma Ltd.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 30
Target enrollment
Dec 2017
Start date
Sep 2026
Expected completion
Interventions / Treatments
GA Depot 40mg once monthlyGA Depot 25mg once monthly
Conditions studied
Primary Progressive Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.